Baoyan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Baoyan Wang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Chenxiao Jiang
Department of Pharmacy, Nanjing Drum Tower Hospital, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China
2 shared publications Peng Xia
Department of Pharmacy, Nanjing Drum Tower Hospital, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China
2 shared publicationsChen Lan
Department of Pharmacy, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China
1 shared publicationDan Han
Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, People’s Republic of China
1 shared publication- Hang Xu
Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China
1 shared publication - Hanwen Tong
Department of Emergency Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 December 2025
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. ume 20, 2467-2480
Real-World Comparative Study of Ultra-Low-Dose Rivaroxaban in Very Elderly Patients with Atrial Fibrillation
Background: Optimal dosing of rivaroxaban in very elderly (≥ 80 years) nonvalvular atrial fibrillation (AF) patients remains debated, particularly concerning ultra-low-dose (5 mg daily) regimens derived from clinician judgement. This study aimed to describe real-world comparative outcomes associated with these clinician-selected dosing regimens. Methods: The study included 1389 very elderly nonvalvular AF patients (≥ 80 years) who received rivaroxaban between January 2018 and December 2022, with 373, 604, and 412 patients receiving 5 mg, 10 mg, and 15/20 mg daily, respectively. Baseline characteristics were balanced using stabilized inverse probability of treatment weighting (IPTW). The outcomes included composite efficacy outcomes (stroke, systemic embolism, myocardial infarction and cardiovascular death) and major bleeding. Subgroup analysis and plasma trough level comparisons were conducted to further assess consistency and pharmacokinetics. Results: The composite efficacy event rates were 9.3%, 6.6%, and 7.0% for the 5 mg, 10 mg, and 15/20 mg groups, respectively. After IPTW, there was no statistically significant difference in composite efficacy outcomes between three groups (HR for 10 mg vs 5 mg: 0.71, 95% CI: 0.44– 1.15; HR for 15/20 mg vs 5 mg: 0.91, 95% CI: 0.52– 1.59). However, major bleeding occurred in 1.6%, 3.6%, and 6.1% of patients, exhibited a dose-dependent increase. The 15/20 mg group had a 4.27-fold higher risk compared to the 5 mg group (HR: 4.27, 95% CI: 1.66– 10.97), while the 10 mg group showed no significant elevation (HR: 2.11, 95% CI: 0.82– 5.40). Subgroup analysis confirmed consistent efficacy and safety trends across specified subgroups. Plasma trough concentrations were significantly higher in the 15/20 mg group compared to the 5 mg group, with no significant difference between the 10 mg and 5 mg groups. Conclusion: In very elderly AF patients, ultra-low-dose rivaroxaban (5 mg daily) provided comparable efficacy to higher doses while significantly reducing major bleeding. This regimen may be a balanced option for high-risk elderly populations.
- 1 December 2025
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. ume 20, 2467-2480
Open AccessReal-World Comparative Study of Ultra-Low-Dose Rivaroxaban in Very Elderly Patients with Atrial Fibrillation
Background: Optimal dosing of rivaroxaban in very elderly (≥ 80 years) nonvalvular atrial fibrillation (AF) patients remains debated, particularly concerning ultra-low-dose (5 mg daily) regimens derived from clinician judgement. This study aimed to describe real-world comparative outcomes associated with these clinician-selected dosing regimens. Methods: The study included 1389 very elderly nonvalvular AF patients (≥ 80 years) who received rivaroxaban between January 2018 and December 2022, with 373, 604, and 412 patients receiving 5 mg, 10 mg, and 15/20 mg daily, respectively. Baseline characteristics were balanced using stabilized inverse probability of treatment weighting (IPTW). The outcomes included composite efficacy outcomes (stroke, systemic embolism, myocardial infarction and cardiovascular death) and major bleeding. Subgroup analysis and plasma trough level comparisons were conducted to further assess consistency and pharmacokinetics. Results: The composite efficacy event rates were 9.3%, 6.6%, and 7.0% for the 5 mg, 10 mg, and 15/20 mg groups, respectively. After IPTW, there was no statistically significant difference in composite efficacy outcomes between three groups (HR for 10 mg vs 5 mg: 0.71, 95% CI: 0.44– 1.15; HR for 15/20 mg vs 5 mg: 0.91, 95% CI: 0.52– 1.59). However, major bleeding occurred in 1.6%, 3.6%, and 6.1% of patients, exhibited a dose-dependent increase. The 15/20 mg group had a 4.27-fold higher risk compared to the 5 mg group (HR: 4.27, 95% CI: 1.66– 10.97), while the 10 mg group showed no significant elevation (HR: 2.11, 95% CI: 0.82– 5.40). Subgroup analysis confirmed consistent efficacy and safety trends across specified subgroups. Plasma trough concentrations were significantly higher in the 15/20 mg group compared to the 5 mg group, with no significant difference between the 10 mg and 5 mg groups. Conclusion: In very elderly AF patients, ultra-low-dose rivaroxaban (5 mg daily) provided comparable efficacy to higher doses while significantly reducing major bleeding. This regimen may be a balanced option for high-risk elderly populations.
- Open Access
- 1 April 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 5311-5327
Time-Varying Effects of Glucocorticoid Treatment in Critically III Patients with Severe Fever with Thrombocytopenia Syndrome: An Inverse Probability of Treatment Weighting Analysis
Purpose: To evaluate the efficacy of glucocorticoid treatment in critically ill patients with severe fever with thrombocytopenia syndrome (SFTS) and to assess whether glucocorticoid use increases the risk of fungal infections. Patients and Methods: A retrospective cohort study was conducted involving confirmed SFTS patients from a tertiary hospital. After applying the Inverse Probability of Treatment Weights (IPTW), multivariable Cox regression and logistic regression analyses were utilized to assess the impact of glucocorticoids on the 28-day mortality rate and the risk of fungal infections. Additionally, landmark analysis and time-varying Cox regression were employed to evaluate the effects of glucocorticoids on mortality across different time intervals. Results: The study included 112 patients with severe SFTS, comprising 67 patients in the glucocorticoid (GC) group and 45 in the non-glucocorticoid (non-GC) group. While glucocorticoid treatment did not significantly alter the overall 28-day mortality in severe SFTS (aHR 0.92, 95% CI 0.44– 1.93, P = 0.828), it was associated with a notable reduction in mortality within the first 7 days of hospitalization (aHR 0.35, 95% CI 0.15– 0.82, P = 0.016) and an increased mortality risk between days 7 and 28 (aHR 4.92, 95% CI 1.30– 18.67, P = 0.019). Furthermore, glucocorticoid use was linked to a significantly higher risk of developing fungal infections (aOR 15.22, 95% CI 4.04– 57.38, P < 0.001). Conclusion: The effects of glucocorticoid treatment in severe SFTS patients vary depending on the disease stage, suggesting that the timing of glucocorticoid administration is crucial. Additionally, the increased risk of fungal infections warrants careful consideration when prescribing glucocorticoids in this population.
- 1 April 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 5311-5327
Open AccessTime-Varying Effects of Glucocorticoid Treatment in Critically III Patients with Severe Fever with Thrombocytopenia Syndrome: An Inverse Probability of Treatment Weighting Analysis
Purpose: To evaluate the efficacy of glucocorticoid treatment in critically ill patients with severe fever with thrombocytopenia syndrome (SFTS) and to assess whether glucocorticoid use increases the risk of fungal infections. Patients and Methods: A retrospective cohort study was conducted involving confirmed SFTS patients from a tertiary hospital. After applying the Inverse Probability of Treatment Weights (IPTW), multivariable Cox regression and logistic regression analyses were utilized to assess the impact of glucocorticoids on the 28-day mortality rate and the risk of fungal infections. Additionally, landmark analysis and time-varying Cox regression were employed to evaluate the effects of glucocorticoids on mortality across different time intervals. Results: The study included 112 patients with severe SFTS, comprising 67 patients in the glucocorticoid (GC) group and 45 in the non-glucocorticoid (non-GC) group. While glucocorticoid treatment did not significantly alter the overall 28-day mortality in severe SFTS (aHR 0.92, 95% CI 0.44– 1.93, P = 0.828), it was associated with a notable reduction in mortality within the first 7 days of hospitalization (aHR 0.35, 95% CI 0.15– 0.82, P = 0.016) and an increased mortality risk between days 7 and 28 (aHR 4.92, 95% CI 1.30– 18.67, P = 0.019). Furthermore, glucocorticoid use was linked to a significantly higher risk of developing fungal infections (aOR 15.22, 95% CI 4.04– 57.38, P < 0.001). Conclusion: The effects of glucocorticoid treatment in severe SFTS patients vary depending on the disease stage, suggesting that the timing of glucocorticoid administration is crucial. Additionally, the increased risk of fungal infections warrants careful consideration when prescribing glucocorticoids in this population.
- 22 June 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 137, 112526
A positive FOXP3/lncRNA SNHG1 feedback axis ameliorates cardiomyocytes hypertrophy by negatively regulating Parkin-mediated mitophagy
- 22 June 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 137, 112526
A positive FOXP3/lncRNA SNHG1 feedback axis ameliorates cardiomyocytes hypertrophy by negatively regulating Parkin-mediated mitophagy
- Open Access
- 1 January 2023
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 29
Efficacy and Safety of Anticoagulant Therapy Versus Antiplatelet Therapy in Acute Ischemic Stroke Patients with Atrial Fibrillation
The efficacy and safety of anticoagulant therapy in patients with acute ischemic stroke (AIS) and atrial fibrillation (AF) remain uncertain. This study enrolled 431 AIS and AF patients from Nanjing Drum Tower Hospital between January 2019 and December 2021 and followed for 365 days to determine the associations between anticoagulants and clinical outcomes by assessing modified Rankin Scale (mRS) score, recurrent ischemic stroke/systemic embolism (IS/SE), all-cause mortality, intracranial hemorrhage (ICH) and major bleeding. Final analysis included 400 eligible patients and divided them into antiplatelet group (n = 191) and anticoagulant group (n = 209). Anticoagulant therapy was associated with excellent (mRS 0–1; adjusted odds ratio (aOR), 2.63; 95% confidence interval (CI), 1.61–4.30) and favorable functional outcomes (mRS 0–2; aOR, 2.82; 95% CI, 1.69–4.70) and lower risk of all-cause mortality (adjusted hazard ratio (aHR), 0.35; 95% CI, 0.21–0.57), ICH (aHR, 0.45; 95% CI, 0.23–0.87) and major bleeding (aHR, 0.51; 95% CI, 0.28–0.94), without increasing the risk of recurrent IS/SE (aHR, 0.75; 95% CI, 0.45–1.24). In conclusion, anticoagulant therapy may be a more effective and safer option than antiplatelet therapy for AIS patients with AF.
- 1 January 2023
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 29
Open AccessEfficacy and Safety of Anticoagulant Therapy Versus Antiplatelet Therapy in Acute Ischemic Stroke Patients with Atrial Fibrillation
The efficacy and safety of anticoagulant therapy in patients with acute ischemic stroke (AIS) and atrial fibrillation (AF) remain uncertain. This study enrolled 431 AIS and AF patients from Nanjing Drum Tower Hospital between January 2019 and December 2021 and followed for 365 days to determine the associations between anticoagulants and clinical outcomes by assessing modified Rankin Scale (mRS) score, recurrent ischemic stroke/systemic embolism (IS/SE), all-cause mortality, intracranial hemorrhage (ICH) and major bleeding. Final analysis included 400 eligible patients and divided them into antiplatelet group (n = 191) and anticoagulant group (n = 209). Anticoagulant therapy was associated with excellent (mRS 0–1; adjusted odds ratio (aOR), 2.63; 95% confidence interval (CI), 1.61–4.30) and favorable functional outcomes (mRS 0–2; aOR, 2.82; 95% CI, 1.69–4.70) and lower risk of all-cause mortality (adjusted hazard ratio (aHR), 0.35; 95% CI, 0.21–0.57), ICH (aHR, 0.45; 95% CI, 0.23–0.87) and major bleeding (aHR, 0.51; 95% CI, 0.28–0.94), without increasing the risk of recurrent IS/SE (aHR, 0.75; 95% CI, 0.45–1.24). In conclusion, anticoagulant therapy may be a more effective and safer option than antiplatelet therapy for AIS patients with AF.
- Open Access
- 1 January 2021
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 27
Combined Effect of MTHFR C677T and PAI-1 4G/5G Polymorphisms on the Risk of Venous Thromboembolism in Chinese Lung Cancer Patients
Venous thromboembolism (VTE) is a common and potentially fatal complication in cancer patients. Although several genetic risk factors related to thrombophilia have been identified, their contributions for the occurrence of VTE in cancer patients have conflicting results. The aim of this study was to evaluated the gene polymorphisms of methylenetetrahydrofolate reductase (MTHFR) C677T and plasminogen activator inhibitor-1 (PAI-1) 4G/5G in lung cancer patients, with and without VTE, and the combined effect on the risk of VTE. 92 lung cancer patients diagnosed with VTE (VTE group) and 122 lung cancer patients without VTE (non-VTE group) were enrolled in the study. The gene polymorphisms were analyzed by the method of polymerase chain reaction-restriction fragment length polymorphism. Gene mutation of factor V Leiden was not detected both in non-VTE group and VTE group. The frequency of MTHFR C677T homozygous mutation in VTE group was 25.00%, higher than that in the non-VTE group without statistical difference. It was found that the PAI-1 4G4G genotype is associated with a higher risk of VTE (OR: 2.62, 95%CI: 1.19-5.75). Interestingly, the interaction between MTHFR C677T and PAI-1 4G/5G polymorphisms showed that the coexistence of the 2 homozygous mutation could further increase the risk of VTE. In conclusion, PAI-1 4G/5G polymorphism may be an increased risk factor for VTE among lung cancer patients in Chinese population. The homozygous MTHFR C677T mutation may be not a risk factor for VTE but increases the risk, accompanied with PAI-1 4G5G genotype.
- 1 January 2021
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 27
Open AccessCombined Effect of MTHFR C677T and PAI-1 4G/5G Polymorphisms on the Risk of Venous Thromboembolism in Chinese Lung Cancer Patients
Venous thromboembolism (VTE) is a common and potentially fatal complication in cancer patients. Although several genetic risk factors related to thrombophilia have been identified, their contributions for the occurrence of VTE in cancer patients have conflicting results. The aim of this study was to evaluated the gene polymorphisms of methylenetetrahydrofolate reductase (MTHFR) C677T and plasminogen activator inhibitor-1 (PAI-1) 4G/5G in lung cancer patients, with and without VTE, and the combined effect on the risk of VTE. 92 lung cancer patients diagnosed with VTE (VTE group) and 122 lung cancer patients without VTE (non-VTE group) were enrolled in the study. The gene polymorphisms were analyzed by the method of polymerase chain reaction-restriction fragment length polymorphism. Gene mutation of factor V Leiden was not detected both in non-VTE group and VTE group. The frequency of MTHFR C677T homozygous mutation in VTE group was 25.00%, higher than that in the non-VTE group without statistical difference. It was found that the PAI-1 4G4G genotype is associated with a higher risk of VTE (OR: 2.62, 95%CI: 1.19-5.75). Interestingly, the interaction between MTHFR C677T and PAI-1 4G/5G polymorphisms showed that the coexistence of the 2 homozygous mutation could further increase the risk of VTE. In conclusion, PAI-1 4G/5G polymorphism may be an increased risk factor for VTE among lung cancer patients in Chinese population. The homozygous MTHFR C677T mutation may be not a risk factor for VTE but increases the risk, accompanied with PAI-1 4G5G genotype.